LX 1606 50mg 50mg | Purity Not Available
Adooq Bioscience
LX 1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity.
More Information Supplier PageLX 1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity.
More Information Supplier PageLX 1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity.
More Information Supplier PageLX 1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity.
More Information Supplier PageLX 1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity.
More Information Supplier PageSL-251188, an oxazolidinone derivative, was characterized in baboons as a radioligand for the in vivo visualization of MAO-B using positron emission tomography (PET).
More Information Supplier PageLY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound A??-lowering effects in animals.
More Information Supplier PageLY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound A??-lowering effects in animals.
More Information Supplier PageLY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound A??-lowering effects in animals.
More Information Supplier PageLY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound A??-lowering effects in animals.
More Information Supplier PageLY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound A??-lowering effects in animals.
More Information Supplier Page